SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Liu YD) "

Sökning: WFRF:(Liu YD)

  • Resultat 1-10 av 76
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  •  
7.
  • Du, QQ, et al. (författare)
  • FASN promotes lymph node metastasis in cervical cancer via cholesterol reprogramming and lymphangiogenesis
  • 2022
  • Ingår i: Cell death & disease. - : Springer Science and Business Media LLC. - 2041-4889. ; 13:5, s. 488-
  • Tidskriftsartikel (refereegranskat)abstract
    • Cervical cancer (CC) patients with lymph node metastasis (LNM) have a poor prognosis. Clarification of the detailed mechanisms underlying LNM may provide potential clinical therapeutic targets for CC patients with LNM. However, the molecular mechanism of LNM in CC is unclear. In the present study, we demonstrated that fatty acid synthase (FASN), one of the key enzymes in lipid metabolism, had upregulated expression in the CC samples and was correlated with LNM. Moreover, multivariate Cox proportional hazards analysis identified FASN as an independent prognostic factor of CC patients. Furthermore, gain-of-function and loss-of-function approaches showed that FASN promoted CC cell migration, invasion, and lymphangiogenesis. Mechanistically, on the one hand, FASN could regulate cholesterol reprogramming and then activate the lipid raft-related c-Src/AKT/FAK signaling pathway, leading to enhanced cell migration and invasion. On the other hand, FASN induced lymphangiogenesis by secreting PDGF-AA/IGFBP3. More importantly, knockdown of FASN with FASN shRNA or the inhibitors C75 and Cerulenin dramatically diminished LNM in vivo, suggesting that FASN plays an essential role in LNM of CC and the clinical application potential of FASN inhibitors. Taken together, our findings uncover a novel molecular mechanism in LNM of CC and identify FASN as a novel prognostic factor and potential therapeutic target for LNM in CC.
  •  
8.
  • Guo, JP, et al. (författare)
  • Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population
  • 2019
  • Ingår i: Annals of the rheumatic diseases. - : BMJ. - 1468-2060 .- 0003-4967. ; 78:6, s. 773-780
  • Tidskriftsartikel (refereegranskat)abstract
    • The strong genetic contribution of the major histocompatibility complex (MHC) region to rheumatoid arthritis (RA) has been generally attributed to human leukocyte antigen (HLA)-DRB1. However, due to the high polymorphisms and linkage disequilibrium within MHC, it is difficult to define novel and/or independent genetic risks using conventional HLA genotyping or chip-based microarray technology. This study aimed to identify novel RA risk variants by performing deep sequencing for MHC.MethodsWe first conducted target sequencing for the entire MHC region in 357 anticitrullinated protein antibodies (ACPA)-positive patients with RA and 1001 healthy controls, and then performed HLA typing in an independent case–control cohort consisting of 1415 samples for validation. All study subjects were Han Chinese. Genetic associations for RA susceptibility and severity were analysed. Comparative modelling was constructed to predict potential functions for the newly discovered RA association variants.ResultsHLA-DQα1:160D conferred the strongest and independent susceptibility to ACPA-positive RA (p=6.16×10−36, OR=2.29). DRβ1:37N had an independent protective effect (p=5.81×10−16, OR=0.49). As predicted by comparative modelling, the negatively charged DQα1:160D stabilises the dimer of dimers, thus may lead to an increased T cell activation. The negatively charged DRβ1:37N encoding alleles preferentially bind with epitope P9 arginine, thus may result in a decreased RA susceptibility.ConclusionsWe provide the first evidence that HLA-DQα1:160D, instead of HLA-DRB1*0405, is the strongest and independent genetic risk for ACPA-positive RA in Han Chinese. Our study also illustrates the value of deep sequencing for fine-mapping disease risk variants in the MHC region.
  •  
9.
  •  
10.
  • Liu, ZF, et al. (författare)
  • Huaier Extract Inhibits Prostate Cancer Growth via Targeting AR/AR-V7 Pathway
  • 2021
  • Ingår i: Frontiers in oncology. - : Frontiers Media SA. - 2234-943X. ; 11, s. 615568-
  • Tidskriftsartikel (refereegranskat)abstract
    • The androgen receptor (AR) plays a pivotal role in prostatic carcinogenesis, and it also affects the transition from hormone sensitive prostate cancer (HSPC) to castration-resistant prostate cancer (CRPC). Particularly, the persistent activation of the androgen receptor and the appearance of androgen receptor splicing variant 7 (AR-V7), could partly explain the failure of androgen deprivation therapy (ADT). In the present study, we reported that huaier extract, derived from officinal fungi, has potent antiproliferative effects in both HSPC and CRPC cells. Mechanistically, huaier extract downregulated both full length AR (AR-FL) and AR-V7 mRNA levels via targeting the SET and MYND domain-containing protein 3 (SMYD3) signaling pathway. Huaier extract also enhanced proteasome-mediated protein degradation of AR-FL and AR-V7 by downregulating proteasome-associated deubiquitinase ubiquitin-specific protease 14 (USP14). Furthermore, huaier extract inhibited AR-FL/AR-V7 transcriptional activity and their nuclear translocation. More importantly, our data demonstrated that huaier extract could re-sensitize enzalutamide-resistant prostate cancer cells to enzalutamide treatment in vitro and in vivo models. Our work revealed that huaier extract could be effective for treatment of prostate cancer either as monotherapy or in combination with enzalutamide.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 76
Typ av publikation
tidskriftsartikel (75)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (71)
övrigt vetenskapligt/konstnärligt (5)
Författare/redaktör
Hall, P (19)
Couch, FJ (19)
Hopper, JL (18)
Brauch, H (18)
Fasching, PA (18)
Beckmann, MW (18)
visa fler...
Cox, A (18)
Nordestgaard, BG (18)
Mannermaa, A (18)
Kataja, V (18)
Kosma, VM (18)
Garcia-Closas, M (18)
Lissowska, J (18)
Chenevix-Trench, G (18)
Benitez, J. (17)
Czene, K (17)
Anton-Culver, H (17)
Giles, GG (17)
Milne, RL (17)
Southey, MC (17)
Hamann, U (17)
Bojesen, SE (17)
Chang-Claude, J (17)
Olson, JE (17)
Blomqvist, C (16)
Dunning, AM (16)
Reed, MWR (16)
Nevanlinna, H (16)
Aittomaki, K (16)
Dork, T (16)
Lindblom, A (15)
Ekici, AB (15)
Fletcher, O (15)
Peto, J (15)
Burwinkel, B (15)
Flesch-Janys, D (15)
Tollenaar, RAEM (15)
Margolin, S (14)
Andrulis, IL (14)
Broeks, A (14)
Shen, CY (14)
Lambrechts, D (14)
Kang, D. (13)
Bruning, T (13)
Schmidt, MK (13)
Johnson, N (13)
Silva, ID (13)
Baglietto, L (13)
Devilee, P (13)
Jakubowska, A (13)
visa färre...
Lärosäte
Karolinska Institutet (73)
Uppsala universitet (13)
Lunds universitet (10)
Umeå universitet (3)
Kungliga Tekniska Högskolan (3)
Högskolan Dalarna (3)
visa fler...
Stockholms universitet (2)
Linköpings universitet (2)
Mittuniversitetet (1)
Chalmers tekniska högskola (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (76)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (23)
Naturvetenskap (3)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy